The Death Knell for Chelation Therapy in Heart Disease

Welcome to Heart Doc VIP! This week, Dr. Kahn tackles a series of mini-topics including the use of colchicine in treating heart disease, the crucial role of oral health in managing atrial fibrillation, and why beta-blockers may not benefit many heart attack patients. Plus, hear Dr. Kahn's thoughts on Valter Longo, Ph.D.'s insights about the "5Ps" that are excessively present in our diets. Also, check out the newly available L-Protein, a plant-based protein, at prolonfmd.com/Drkahn. Our main discussion centers on the recent findings from the TACT2 trial, where intravenous chelation therapy in 1,000 heart patients followed over four years failed to improve outcomes. This result is particularly disheartening following the promising TACT trial published in 2013, and it likely signals the end of funded research for chelation therapy.